Mortality of bullous pemphigoid in Switzerland: A prospective study

British Journal of Dermatology

Volumn 165, Issue 2, 2011, Pages 368-374

  Cortes B ^a,b   Marazza, G ^c   Naldi, L ^d   Combescure, C ^a   Borradori, L ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^d OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BULLOUS PEMPHIGOID; CHILD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; OVERALL SURVIVAL; POPULATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; SWITZERLAND;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CHILD; COMORBIDITY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PEMPHIGOID, BULLOUS; PROGNOSIS; PROSPECTIVE STUDIES; SWITZERLAND; YOUNG ADULT;

EID: 79960621960     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10413.x     Document Type: Article

References (42)

1. Zillikens D, Wever S, Roth A, et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995; 131: 957-8.
2. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48-52.
3. Di Zenzo G, Marazza G, Borradori L,. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol 2007; 23: 257-88.
4. Hertl M,. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 2000; 122: 91-100. (Pubitemid 30435683)
5. Nousari HC, Anhalt GJ,. Pemphigus and bullous pemphigoid. Lancet 1999; 354: 667-72. (Pubitemid 29391440)
6. Stanley JR,. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 1993; 53: 291-325.
7. Nanda A, Al-Saeid K, Al-Sabah H, et al. Clinicoepidemiological features and course of 43 cases of bullous pemphigoid in Kuwait. Clin Exp Dermatol 2006; 31: 339-42.
8. Serwin AB, Bokiniec E, Piascik M, et al. Epidemiological and clinical analysis of pemphigoid patients in northeastern Poland in 2000-2005. Med Sci Monit 2007; 13: CR360-4. (Pubitemid 47359103)
9. Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol 1999; 41: 266-8. (Pubitemid 29379717)
10. Cozzani E, Parodi A, Rebora A, et al. Bullous pemphigoid in Liguria: a 2-year survey. J Eur Acad Dermatol Venereol 2001; 15: 317-19. (Pubitemid 33014841)
11. Bertram F, Brocker EB, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009; 7: 434-40.
12. Gudi VS, White MI, Cruickshank N, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol 2005; 153: 424-7. (Pubitemid 41228445)
13. Marazza G, Pham HC, Scharer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861-8.
14. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.
15. Waisbourd-Zinman O, Ben-Amitai D, Cohen AD, et al. Bullous pemphigoid in infancy: clinical and epidemiologic characteristics. J Am Acad Dermatol 2008; 58: 41-8. (Pubitemid 350298140)
16. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-7. (Pubitemid 34438839)
17. Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214-21.
18. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 2007; 143: 1536-42. (Pubitemid 350277770)
19. Gurcan HM, Ahmed AR,. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009; 161: 723-31.
20. Bernard P, Reguiai Z, Tancrede-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009; 145: 537-42.
21. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141: 691-8. (Pubitemid 41001068)
22. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002; 138: 903-8. (Pubitemid 34700736)
23. Bernard P, Bedane C, Bonnetblanc JM,. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 1997; 136: 694-8. (Pubitemid 27278076)
24. Bailar JC III, Ederer EF,. Significance factors for the ratio of a Poisson variable to its expectation. Biometrics 1964; 20: 639-43.
25. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134: 465-9. (Pubitemid 28207630)
26. Bernard P, Enginger V, Venot J, et al. Survival prognosis in pemphigoid. A cohort analysis of 78 patients. Ann Dermatol Venereol 1995; 122: 751-7. (Pubitemid 26072684)
27. Garcia-Doval I, Conde Taboada A, Cruces Prado MJ,. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. J Invest Dermatol 2005; 124: 666-7. (Pubitemid 40381593)
28. Doffoel-Hantz V, Sparsa A, Marin B, et al. One year follow-up of patients with bullous pemphigoid. Ann Dermatol Venereol 2009; 136: 407-11.
29. Venning VA, Wojnarowska F,. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992; 26: 585-9.
30. Colbert RL, Allen DM, Eastwood D, et al. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004; 122: 1091-5. (Pubitemid 38651080)
31. Ahmed AR, Maize JC, Provost TT,. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977; 113: 1043-6. (Pubitemid 8163451)
32. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 1994; 130: 753-8. (Pubitemid 24182685)
33. Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008; 59: 582-8.
34. Chosidow O, Doppler V, Bensimon G, et al. Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease? Arch Dermatol 2000; 136: 521-4. (Pubitemid 30212964)
35. Cordel N, Chosidow O, Hellot MF, et al. Neurological disorders in patients with bullous pemphigoid. Dermatology 2007; 215: 187-91. (Pubitemid 47378983)
36. Foureur N, Descamps V, Lebrun-Vignes B, et al. Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases with bullous pemphigoid? Eur J Dermatol 2001; 11: 230-3. (Pubitemid 32472675)
37. Garcia-Estevez DA, Peon-Curras G, Bal-Nieves F,. Bullous pemphigoid and amyotrophic lateral sclerosis. Rev Neurol 2008; 47: 525-6.
38. Stinco G, Mattighello P, Zanchi M, et al. Multiple sclerosis and bullous pemphigoid: a casual association or a pathogenetic correlation? Eur J Dermatol 2002; 12: 186-8. (Pubitemid 34194178)
39. Stinco G, Codutti R, Scarbolo M, et al. A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases. Acta Derm Venereol 2005; 85: 136-9. (Pubitemid 40477663)
40. Langan SM, Groves RW, West J,. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131: 63-6.
41. Laffitte E, Burkhard PR, Fontao L, et al. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol 2005; 152: 537-40. (Pubitemid 40547129)
42. Li L, Chen J, Wang B, et al. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160: 1343-5.